Jakarta - PT Kalbe Farma Tbk (KLBF) has revised its net sales growth target to around 11-13% YoY this year.

"With a projected profit growth of around 11-13%," Kalbe Corporate Secretary Lukito Gozali said in a statement on Tuesday (26/10).

According to Lukito, the company also maintains a capital expenditure budget of Rp1 trillion, which will expand production and distribution capacity.

The company maintains a dividend payout ratio at a 45-55% ratio, taking into account the availability of funds and internal funding needs.

Kalbe also innovates through PT Kalbe Genexine Biologics by conducting research collaborations and clinical trials with third parties for novel products in several countries in Southeast Asia, Australia, and the Middle East.

"Kalbe's optimism for growth encourages the company to consistently carry out research and development activities," he explained.

Through ABGC (Academ